相关实验视频
Updated: Mar 14, 2026

11:31
Evaluation of the Storage Stability of Extracellular Vesicles
Published on: May 22, 2019
15.2K
结构-活动关系研究 作为细胞外囊泡的诱导剂的替代氧化醇
Nikunj M Shukla1, Tyler D Brown2, Michael Chan2
1Department of Medicine, University of California San Diego, 9500 Gilam Dr., La Jolla, California 92093, United States.
Journal of medicinal chemistry
|March 13, 2026
概括
研究人员发现了一种新型化合物,可以增强免疫刺激细胞外囊泡 (EV) 释放,并促进抗癌免疫反应. 这种化合物,39,准布林聚合,并显示了癌症治疗和免疫治疗的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 细胞外囊泡 (EVs) 在细胞间通信和免疫调节中起着至关重要的作用.
- 小分子化合物可以调节EV释放和功能.
- 识别新型免疫调节剂对于治疗进展至关重要.
研究的目的:
- 对先前识别的免疫调节化合物 (化合物1) 进行结构活性关系 (SAR) 研究.
- 为了识别增强四素 (CD63) 记者活性的类似物,EV生物发生和释放的标记物.
- 评估新型化合物作为治疗癌症和免疫疗法的治疗剂的潜力.
主要方法:
- 使用高通量查和SAR研究来识别强效的类似物.
- 人类的THP-1细胞被用来评估CD63记者活性.
- 对抗原呈现细胞进行了分析,以检测细胞因子和共刺激分子的表达.
- 评估了抗原与CD8+T细胞的交叉呈现.
- 进行了分子对接研究,以预测作用机制.
- 细胞活力测定是在增殖细胞上进行的.
主要成果:
- 鉴定出一种强效的类似物,即化合物39,显著增强了CD63的记者活性.
- 化合物39刺激了抗原呈现细胞中的免疫刺激性细胞因子和辅助刺激分子表达.
- 化合物39促进了对CD8+T细胞的抗原交叉呈现.
- 分子对接建议的化合物39干扰氨酸聚合,可能与β-氨酸诺可达结合部位结合.
- 化合物39优先影响增殖细胞的活力.
结论:
- 化合物39是一种强大的免疫调节剂,可增强EV释放并促进抗癌免疫反应.
- 化合物39的机制涉及干扰氨酸聚合的过程.
- 化合物39显示出作为癌症和免疫疗法的治疗剂的潜力,这是由于它对增殖细胞的选择性毒性.
相关概念视频
Intralumenal Vesicles and Multivesicular Bodies
5.1K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
5.1K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
Pinching-off of Coated Vesicles
4.4K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
4.4K
Receptor-mediated Endocytosis
11.1K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
11.1K

